A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia

Iregui, 2002, Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia, Chest, 122, 262, 10.1378/chest.122.1.262

Bekaert, 2011, Attributable mortality of ventilator-associated pneumonia: a reappraisal using causal analysis, Am J Respir Crit Care Med, 184, 1133, 10.1164/rccm.201105-0867OC

Kollef, 2012, Economic impact of ventilator-associated pneumonia in a large matched cohort, Infect Control Hosp Epidemiol, 33, 250, 10.1086/664049

Sievert, 2013, Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010, Infect Control Hosp Epidemiol, 34, 1, 10.1086/668770

Lodise, 2011, Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia, Antimicrob Agents Chemother, 55, 1606, 10.1128/AAC.01330-10

Ehrmann, 2013, Aerosol therapy during mechanical ventilation: an international survey, Intensive Care Med, 39, 1048, 10.1007/s00134-013-2872-5

Palmer, 2014, Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit, Am J Respir Crit Care Med, 189, 1225, 10.1164/rccm.201312-2161OC

Lu, 2011, Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa, Am J Respir Crit Care Med, 184, 106, 10.1164/rccm.201011-1894OC

Lu, 2012, Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, Anesthesiology, 117, 1335, 10.1097/ALN.0b013e31827515de

Arnold, 2012, Use of adjunctive aerosolized antimicrobial therapy in the treatment of Pseudomonas aeruginosa and Acinetobacter baumannii ventilator-associated pneumonia, Respir Care, 57, 1226, 10.4187/respcare.01556

Montgomery, 2014, Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible Gram-negative respiratory tract pathogens, Antimicrob Agents Chemother, 58, 3714, 10.1128/AAC.02780-13

Montgomery, 2014, Amikacin-fosfomycin at a five-to-two ratio: characterization of mutation rates in microbial strains causing ventilator-associated pneumonia and interactions with commonly used antibiotics, Antimicrob Agents Chemother, 58, 3708, 10.1128/AAC.02779-13

Montgomery, 2014, A randomized double-blind placebo-controlled dose-escalation phase 1 study of aerosolized amikacin and fosfomycin delivered via the PARI investigational eFlow® Inline nebulizer system in mechanically ventilated patients, J Aerosol Med Pulm Drug Deliv, 27, 441, 10.1089/jamp.2013.1100

Li Bassi G, Aguilera E, Chiurazzi C, et al. The effects of nebulized amikacin/fosfomycin and systemic meropenem on severe amikacin-resistant meropenem-susceptible Pseudomonas aeruginosa pneumonia. Abstract presented at: European Congress of Clinical Microbiology and Infectious Diseases Meeting; April 9-12, 2016; Amsterdam, The Netherlands.

Singh, 2000, Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription, Am J Respir Crit Care Med, 162, 505, 10.1164/ajrccm.162.2.9909095

Pocock, 2012, The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities, Eur Heart J, 33, 176, 10.1093/eurheartj/ehr352

Miller, 2003, Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation, Am J Respir Crit Care Med, 168, 1205, 10.1164/rccm.200210-1167OC

Huang, 2015, Mucin binding reduces colistin antimicrobial activity, Antimicrob Agents Chemother, 59, 5925, 10.1128/AAC.00808-15

Eschenbacher, 1984, Alteration in osmolarity of inhaled aerosols cause bronchoconstriction and cough, but absence of a permeant anion causes cough alone, Am Rev Respir Dis, 129, 211

Hahn, 2009, In vitro assessment of a novel nebulizer for mechanically ventilated patients based on the eFlow® technology, J Aerosol Med Pulm Drug Deliv, 22, 187

O'Riordan, 1994, Aerosol deposition in mechanically ventilated patients. Optimizing nebulizer delivery, Am Respir Crit Care Med, 149, 214, 10.1164/ajrccm.149.1.8111585

Fihman, 2015, Five-year trends for ventilator-associated pneumonia: correlation between microbiological findings and antimicrobial drug consumption, Int J Antimicrob Agents, 46, 518, 10.1016/j.ijantimicag.2015.07.010